Circulating tumor cells and CDX models as a tool for preclinical drug development.
Affiliation
Clinical and Experimental Pharmacology Group, Cancer Research UK Manchester Institute, University of Manchester, ManchesterIssue Date
2017-08
Metadata
Show full item recordAbstract
Lung cancers are the main cause of cancer-related deaths worldwide. Efforts placed to improve the survival of lung cancer patients and untangle the complexity of this disease, have resulted in the generation of hundreds of lung cancer cell lines and several genetically engineered mouse models (GEMMs). Although these research tools have extended our knowledge of lung cancer, improvement in the clinical care of lung cancer patients have been limited overall, with measured optimism regarding initial responses to targeted therapies in stratified subgroups of patients. Patient-derived xenograft (PDX) models are beginning to assist 'personalized therapy' approaches particularly in non-small cell lung cancer (NSCLC) however biopsies of lung cancers to generate PDXs are not without challenges and risks to the patient. Liquid biopsies, on the other hand, are a rapid and non-invasive procedure allowing the collection of circulating tumor cells (CTCs) with a single 10 mL blood draw. These CTCs recapitulate the molecular heterogeneity of the corresponding tumors and, therefore, can be used as surrogates to study tumor biology and generate new patient-derived models. Here, we discuss the CTC-derived models that have been generated, most notably in small cell lung cancer (SCLC), highlighting challenges and opportunities related to these novel preclinical tools.Citation
Circulating tumor cells and CDX models as a tool for preclinical drug development. 2017, 6 (4):397-408 Transl Lung Cancer ResJournal
Translational Lung Cancer ResearchDOI
10.21037/tlcr.2017.08.01PubMed ID
28904884Type
ArticleLanguage
enISSN
2218-6751ae974a485f413a2113503eed53cd6c53
10.21037/tlcr.2017.08.01
Scopus Count
Collections
Related articles
- Tumorigenic circulating tumor cells from xenograft mouse models of non-metastatic NSCLC patients reveal distinct single cell heterogeneity and drug responses.
- Authors: Suvilesh KN, Nussbaum YI, Radhakrishnan V, Manjunath Y, Avella DM, Staveley-O'Carroll KF, Kimchi ET, Chaudhuri AA, Shyu CR, Li G, Pantel K, Warren WC, Mitchem JB, Kaifi JT
- Issue date: 2022 Mar 12
- Tumourigenic non-small-cell lung cancer mesenchymal circulating tumour cells: a clinical case study.
- Authors: Morrow CJ, Trapani F, Metcalf RL, Bertolini G, Hodgkinson CL, Khandelwal G, Kelly P, Galvin M, Carter L, Simpson KL, Williamson S, Wirth C, Simms N, Frankliln L, Frese KK, Rothwell DG, Nonaka D, Miller CJ, Brady G, Blackhall FH, Dive C
- Issue date: 2016 Jun
- Brief report on the clinical characteristics of patients whose samples generate small cell lung cancer circulating tumour cell derived explants.
- Authors: Vickers AJ, Frese K, Galvin M, Carter M, Franklin L, Morris K, Pierce J, Descamps T, Blackhall F, Dive C, Carter L
- Issue date: 2020 Dec
- Circulating tumor cells (CTCs) for the noninvasive monitoring and personalization of non-small cell lung cancer (NSCLC) therapies.
- Authors: Pawlikowska P, Faugeroux V, Oulhen M, Aberlenc A, Tayoun T, Pailler E, Farace F
- Issue date: 2019 Jan
- Genomic and Functional Fidelity of Small Cell Lung Cancer Patient-Derived Xenografts.
- Authors: Drapkin BJ, George J, Christensen CL, Mino-Kenudson M, Dries R, Sundaresan T, Phat S, Myers DT, Zhong J, Igo P, Hazar-Rethinam MH, Licausi JA, Gomez-Caraballo M, Kem M, Jani KN, Azimi R, Abedpour N, Menon R, Lakis S, Heist RS, Büttner R, Haas S, Sequist LV, Shaw AT, Wong KK, Hata AN, Toner M, Maheswaran S, Haber DA, Peifer M, Dyson N, Thomas RK, Farago AF
- Issue date: 2018 May